INmune Bio to Showcase Late-Stage Pipeline at H.C. Wainwright Conference
Event summary
- INmune Bio (NASDAQ: INMB) will present at the H.C. Wainwright Global Investment Conference on September 14, 2026.
- CEO David Moss will host one-on-one meetings with institutional investors from September 14-16.
- The company is advancing two late-stage product platforms: CORDStrom™ and XPro1595™.
- CORDStrom™ is targeting regulatory filings in the UK (2026) and EU (2027), with a U.S. BLA submission planned.
- XPro1595™ has received FDA Fast Track designation and is moving toward a Phase 2b/3 registrational program.
The big picture
INmune Bio’s presentation at the H.C. Wainwright Conference comes as the company positions itself for key regulatory milestones in its two late-stage platforms. The biotech sector is increasingly focused on precision medicine and immune-targeting therapies, making INmune Bio’s progress in CORDStrom™ and XPro1595™ strategically significant. The company’s ability to secure investor confidence and regulatory approvals will be pivotal in its next phase of growth.
What we're watching
- Regulatory Momentum
- The pace at which CORDStrom™ advances through UK and EU regulatory filings will determine its commercialization timeline.
- Clinical Execution
- Whether XPro1595™ can successfully navigate its Phase 2b/3 program will be critical for its Fast Track designation.
- Investor Sentiment
- How institutional investors react to INmune Bio’s pipeline updates could impact its market positioning.
Related topics